Bibiana Cabrera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bibiana Cabrera has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Miquel Bernardo
Ciber de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
20 shared publications - Miquel Bioque
Barcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Instituto de Salud Carlos III (ISCIII), Department of Medicine, University of Barcelona, Barcelona, Spain
17 shared publications - Iluminada Corripio
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
12 shared publications - Eduard Vieta
Hospital Clínic de Barcelona
10 shared publications Ana González-Pinto
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; BIOARABA Health Research Institute, OSI Araba, University Hospital, University of the Basque Country, Vitoria, Spain
9 shared publicationsAntonio Lobo
Department of Medicine and Psychiatry, University of Zaragoza, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain
9 shared publications
Latest Publications
- 1 March 2018
- Published by Elsevier in Schizophrenia Research
- Vol. 193, 188-196
Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis
- 1 March 2018
- Published by Elsevier in Schizophrenia Research
- Vol. 193, 188-196
Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis
- 1 March 2018
- Published by Elsevier in Psychiatry Research
- Vol. 261, 68-72
Detection of early psychotic symptoms: Validation of the Spanish version of the “Symptom Onset in Schizophrenia (SOS) inventory”
- 1 March 2018
- Published by Elsevier in Psychiatry Research
- Vol. 261, 68-72
Detection of early psychotic symptoms: Validation of the Spanish version of the “Symptom Onset in Schizophrenia (SOS) inventory”
- 27 December 2017
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 78 (9) , 1414-1422
Persistent Negative Symptoms in First-Episode Psychosis
From The Journal of Clinical Psychiatry: Although negative symptoms of psychosis may be less prominent than positive symptoms, they can still have an equally great impact on patient functioning. This study of patients with a first episode of psychosis compares characteristics of those who did and did not experience persistent negative symptoms.
- 27 December 2017
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 78 (9) , 1414-1422
Persistent Negative Symptoms in First-Episode Psychosis
From The Journal of Clinical Psychiatry: Although negative symptoms of psychosis may be less prominent than positive symptoms, they can still have an equally great impact on patient functioning. This study of patients with a first episode of psychosis compares characteristics of those who did and did not experience persistent negative symptoms.
- 21 November 2017
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 268 (7) , 699-711
Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study
Individual changes over time in cognition in patients with psychotic disorders have been studied very little, especially in the case of first episode psychosis (FEP). We aimed to establish whether change in individual trajectories in cognition over 2 years of a sample of 159 FEP patients was reliable and clinically significant, using the reliable change index (RCI) and clinically significant change (CSC) methods. We also studied a sample of 151 matched healthy controls. Patients and controls were assessed with a set of neuropsychological tests, as well as premorbid, clinical and functionality measures. We analysed the course of cognitive measures over time, using analysis of variance, and the individual trajectories in the cognitive measures with the regression-based RCI (RCISRB) and the CSC. The RCISRB showed that between 5.4 and 31.2% of the patients showed deterioration patterns, and between 0.6 and 8.8% showed improvement patterns in these tests over time. Patients showing better cognitive profiles according to RCISRB (worsening in zero to two cognitive measures) showed better premorbid, clinical and functional profiles than patients showing deterioration patterns in more than three tests. When combining RCISRB and CSC values, we found that less than 10% of patients showed improvement or deterioration patterns in executive function and attention measures. These results support the view that cognitive impairments are stable over the first 2 years of illness, but also that the analysis of individual trajectories could help to identify a subgroup of patients with particular phenotypes, who may require specific interventions.
- 21 November 2017
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 268 (7) , 699-711
Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study
Individual changes over time in cognition in patients with psychotic disorders have been studied very little, especially in the case of first episode psychosis (FEP). We aimed to establish whether change in individual trajectories in cognition over 2 years of a sample of 159 FEP patients was reliable and clinically significant, using the reliable change index (RCI) and clinically significant change (CSC) methods. We also studied a sample of 151 matched healthy controls. Patients and controls were assessed with a set of neuropsychological tests, as well as premorbid, clinical and functionality measures. We analysed the course of cognitive measures over time, using analysis of variance, and the individual trajectories in the cognitive measures with the regression-based RCI (RCISRB) and the CSC. The RCISRB showed that between 5.4 and 31.2% of the patients showed deterioration patterns, and between 0.6 and 8.8% showed improvement patterns in these tests over time. Patients showing better cognitive profiles according to RCISRB (worsening in zero to two cognitive measures) showed better premorbid, clinical and functional profiles than patients showing deterioration patterns in more than three tests. When combining RCISRB and CSC values, we found that less than 10% of patients showed improvement or deterioration patterns in executive function and attention measures. These results support the view that cognitive impairments are stable over the first 2 years of illness, but also that the analysis of individual trajectories could help to identify a subgroup of patients with particular phenotypes, who may require specific interventions.
- 1 November 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 189, 196-203
Gene-environment interaction as a predictor of early adjustment in first episode psychosis
- 1 November 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 189, 196-203
Gene-environment interaction as a predictor of early adjustment in first episode psychosis
- 1 November 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 189, 84-90
The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study
- 1 November 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 189, 84-90
The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study
- 1 November 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 189, 181-189
Modelling gene-environment interaction in first episodes of psychosis
- 1 November 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 189, 181-189
Modelling gene-environment interaction in first episodes of psychosis
- 1 April 2017
- Published by Elsevier in Psychiatry Research
- Vol. 250, 38-43
Cannabis use, COMT, BDNF and age at first-episode psychosis
- 1 April 2017
- Published by Elsevier in Psychiatry Research
- Vol. 250, 38-43
Cannabis use, COMT, BDNF and age at first-episode psychosis
- 3 February 2017
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 41 (1) , 42-46
Metabolic syndrome or glucose challenge in first episode of psychosis?
Patients with schizophrenia exhibit a reduced life expectancy. Although unhealthy lifestyle or suicide risk plays a role, the main causes are diverse medical conditions such as cardiovascular diseases, type 2 diabetes mellitus and metabolic syndrome. Albeit pharmacological secondary side effects might also trigger previous conditions, studies in naïve patients reflect diverse anomalies at the onset. Patients with a first episode of psychosis, display a wide scope of metabolic abnormalities, ranging from normality till pathological values depending on the parameters studied. We attempted to evaluate the metabolic syndrome and glycemic homeostasis in a subset of antipsychotic-naïve patients with a first episode of non-affective psychosis. Patients (n= 84) showed a similar prevalence of metabolic syndrome compared with a matched control sample (n= 98) (6% vs 4%,P= 0.562), while glucose homeostasis values differed significantly (14% vs. 5%,P= 0.034). Our results suggest that metabolic syndrome is not a useful clinical condition to be evaluated in patients before pharmacological treatment. Abnormal glycemic homeostasis at the onset of the disease requires specific diagnostic tools and preventive measures in order to avoid future cardiovascular events. New strategies must be implemented in order to evaluate the cardiovascular risk and subsequent morbidity in patients at the onset of the disease.
- 3 February 2017
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 41 (1) , 42-46
Metabolic syndrome or glucose challenge in first episode of psychosis?
Patients with schizophrenia exhibit a reduced life expectancy. Although unhealthy lifestyle or suicide risk plays a role, the main causes are diverse medical conditions such as cardiovascular diseases, type 2 diabetes mellitus and metabolic syndrome. Albeit pharmacological secondary side effects might also trigger previous conditions, studies in naïve patients reflect diverse anomalies at the onset. Patients with a first episode of psychosis, display a wide scope of metabolic abnormalities, ranging from normality till pathological values depending on the parameters studied. We attempted to evaluate the metabolic syndrome and glycemic homeostasis in a subset of antipsychotic-naïve patients with a first episode of non-affective psychosis. Patients (n= 84) showed a similar prevalence of metabolic syndrome compared with a matched control sample (n= 98) (6% vs 4%,P= 0.562), while glucose homeostasis values differed significantly (14% vs. 5%,P= 0.034). Our results suggest that metabolic syndrome is not a useful clinical condition to be evaluated in patients before pharmacological treatment. Abnormal glycemic homeostasis at the onset of the disease requires specific diagnostic tools and preventive measures in order to avoid future cardiovascular events. New strategies must be implemented in order to evaluate the cardiovascular risk and subsequent morbidity in patients at the onset of the disease.
- 1 October 2016
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 38, 61-69
Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders
Objective: A functional polymorphism of the brain-derived neurotrophic factor gene (BDNF) Val66Met has been associated with cognitive function and symptom severity in patients with schizophrenia. It has been suggested that the Val66Met polymorphism has a role as a modulator in a range of clinical features of the illness, including symptoms severity, therapeutic responsiveness, age of onset, brain morphology and cognitive function. However, little work has been done in first-episode schizophrenia (FES) spectrum disorders. The objective of this study is to investigate the association of the BDNF Val66Met polymorphism on cognitive function and clinical symptomatology in FES patients.Methods: Using a cross-sectional design in a cohort of 204 patients with FES or a schizophrenia spectrum disorder and 204 healthy matched controls, we performed BDNF Val66Met genotyping and tested its relationship with cognitive testing (attention, working memory, learning/verbal memory and reasoning/problem-solving) and assessment of clinical symptom severity.Results: There was no significant influence of the BDNF allele frequency on cognitive factor scores in either patients or controls. An augmented severity of negative symptoms was found in FES patients that carried the Met allele.Conclusions: The results of this study suggest that in patients with a first-episode of schizophrenia or a schizophrenia spectrum disorder, the BDNF Val66Met polymorphism does not exert an influence on cognitive functioning, but is associated with negative symptoms severity. BDNF may serve as suitable marker of negative symptomatology severity in FES patients within the schizophrenia spectrum.
- 1 October 2016
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 38, 61-69
Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders
Objective: A functional polymorphism of the brain-derived neurotrophic factor gene (BDNF) Val66Met has been associated with cognitive function and symptom severity in patients with schizophrenia. It has been suggested that the Val66Met polymorphism has a role as a modulator in a range of clinical features of the illness, including symptoms severity, therapeutic responsiveness, age of onset, brain morphology and cognitive function. However, little work has been done in first-episode schizophrenia (FES) spectrum disorders. The objective of this study is to investigate the association of the BDNF Val66Met polymorphism on cognitive function and clinical symptomatology in FES patients.Methods: Using a cross-sectional design in a cohort of 204 patients with FES or a schizophrenia spectrum disorder and 204 healthy matched controls, we performed BDNF Val66Met genotyping and tested its relationship with cognitive testing (attention, working memory, learning/verbal memory and reasoning/problem-solving) and assessment of clinical symptom severity.Results: There was no significant influence of the BDNF allele frequency on cognitive factor scores in either patients or controls. An augmented severity of negative symptoms was found in FES patients that carried the Met allele.Conclusions: The results of this study suggest that in patients with a first-episode of schizophrenia or a schizophrenia spectrum disorder, the BDNF Val66Met polymorphism does not exert an influence on cognitive functioning, but is associated with negative symptoms severity. BDNF may serve as suitable marker of negative symptomatology severity in FES patients within the schizophrenia spectrum.